


RealRate

PHARMACEUTICAL 2023











PHARMACEUTICAL 2023





The relative strengths and weaknesses of XBiotech Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XBiotech Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 63% points. The greatest weakness of XBiotech Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 12% points.

The company's Economic Capital Ratio, given in the ranking table, is 302%, being 259% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	219,843
Cost of Goods Sold	651
Intangible Assets	0
Liabilities, Current	4,066
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-1,145
Other Expenses	-688
Other Liabilities	1,635
Other Net Income	902
Other Revenues	4,010
Property and Equipment	26,260
Research and Development	31,544
Selling, General and Administrative Expense	6,305

Output Variable	Value in 1000 USD
Assets	246,103
Liabilities	5,701
Expenses	37,812
Revenues	4,010
Stockholders Equity	240,402
Net Income	-32,900
Comprehensive Net Income	-33,472
Economic Capital Ratio	302%

